LNC Therapeutics raises €6.5m to reinforce its R&D in the microbiota field

47e64bcf-896e-4bc0-b4db-413992dc9498articleimage.jpg

29 Sep 2017 --- LNC Therapeutics, a company specialized in the research and development of gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases, has raised a €6.5 million (US$7.67 million) Series C funding round. This new round, co-led by Seventure Partners, brings together a consortium of investors and a family office. Additionally, the company has appointed a new chief scientific officer, Dr. Sandrine Claus, to lead the gut microbiota project.

“This funding round of €6.5 million establishes LNC Therapeutics as a key player in the treatment of obesity and metabolic disorders through an action on the gut microbiota,” explains Jean-Luc Treillou, LNC therapeutics’ CEO. 

“Our recent clinical trial on obese patients indicated that visceral fat loss in this population was correlated with a modulation of the gut microbiota, specifically with a bacterial family known for its anti-obesity potential,” Treillou adds.

“Hence, our current objective is to develop new drug candidates whose mechanism of action requires interaction with the gut microbiota and the intestinal membrane. Targeted therapeutic indications include pathologies caused by excessive visceral fat accumulation and chronic inflammation such as obesity and NASH.”

“The presentation of our development plan is scheduled in the first quarter of 2018 and will include targets and project milestones,” Caroline Bernard, Strategic Development Project Manager at LNC Therapeutics, tells NutritionInsight.

Regarding the populations LNC Therapeutics intends to target its research on, Bernard adds that LNC will indeed focus on some specific (but still large) sub-populations to maximize clinical outcomes, but did not provide further details on these sub-populations.

Click to EnlargeNew CSO
Newly appointed Chief Scientific Officer Sandrine Claus, Ph.D., is Associate Professor in Integrative Metabolism at the University of Reading, which she joined in 2010. Its research focuses on the host-gut microbial metabolic interactions to link gut microbial ecology to metabolic health.

Claus’ mission within LNC Therapeutics will be leading the ambitious R&D pipeline and the development of new treatments in the field of cardiometabolic diseases and other fields of investigation relating to the bioactivity of some peptides.

“It is with great pleasure that I am joining LNC Therapeutics and its dynamic team. It is an exciting time to join a company which owns a large pipeline of innovative patents related to gut microbiota activity, aimed at improving health outcomes,” comments Sandrine Claus.

“Our new CSO, Dr. Sandrine Claus, Ph.D., who is an expert on the role of gut microbiota in the development of metabolic disorders, is a strategic recruitment. Our strategic plan now has to be delivered and will drive us to an IPO by the end of 2019,” concludes Jean-Luc Treillou.

“We are pleased to participate in this new round and to have syndicated the Series C with other ‘deep pocket’ investors. LNC Therapeutics, a company we have supported since the Series A, chose to remain discreet over the last two years in the booming universe of the microbiome, to gain a foothold and consolidate its competitive position. LNC Therapeutics is complementing our portfolio of microbiome champions, consisting of companies that are advanced in their research,” adds Isabelle de Crémoux, CEO of Seventure Partners and founder of Health For Life Capital.

By Lucy Gunn

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Health & Nutrition News

Drink up: Tea polyphenols may promote lower gut health

09 Nov 2018 --- A University of Naples study has found that polyphenols found in tea can be beneficial to lower gut health. The purpose of the study was to evaluate the colon bioaccessibility and antioxidant activity of tea polyphenolic extract. The findings of the study could present a novel strategy for the management of gut-related inflammatory diseases.

Health & Nutrition News

World’s first celiac vaccine enters international Phase 2 trial

07 Nov 2018 --- The world's first vaccine for people who have celiac disease is to be rolled out in an international trial. If successful, the vaccine, Nexvax2, would be the first medicine of its kind for people with the disease. Currently, following a gluten-free diet is the only treatment, but even the most diligent patients can suffer the adverse effects of accidental exposure. Therefore, the results of the vaccine’s trial may be eagerly awaited by those avoiding gluten due to their celiac condition.

Health & Nutrition News

Weekly Roundup: US researchers granted Danisco Foundation Science Award, polyphenol-rich extract may improve declining senior cognition

19 Oct 2018 --- This week in nutrition, a study found that grape-blueberry extract may improve cognition in at-risk older adults. Pet medication and wellness company PetIQ completed its acquisition of pet supplement manufacturer HBH. The Danisco Foundation awarded two Science Excellence Awards for 2018 and the American Herbal Products Association (AHPA) Botanical Raw Materials Committee launched a Sustainability Subcommittee. To mark its 40th “ruby” anniversary, plant-based ingredients company BI will be showcasing “ruby” colored beverages at SupplySide West 2018, in Las Vegas.

Health & Nutrition News

Microbiome may play a role in development of multiple sclerosis, study finds

17 Oct 2018 --- Gastrointestinal microbiota could play a far greater role in the pathogenesis of multiple sclerosis (MS), researchers at the University of Zurich have identified. The study noted that immune cells that are activated in the intestine migrate to the brain, where they may cause an “inflammatory cascade.” The researchers suggest that it is worth broadening the research perspective to gain a better understanding of the pathological processes.

Health & Nutrition News

Intermittent fasting strategy may help reverse Type 2 diabetes, suggests case study

12 Oct 2018 --- Planned intermittent fasting may help to reverse Type 2 diabetes, suggest doctors writing in the journal BMJ Case Reports. Their suggestion comes after three patients in their care were able to cut out the need for insulin treatment altogether following an intermittent fasting strategy.

More Articles
URL : http://www.nutritioninsight.com:80/news/lnc-therapeutics-raises-65m-to-reinforce-its-rd-in-the-microbiota-field.html